The Technical Analyst
Molecular Partners AG [MOLN]
Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
Molecular Partners AG Price, Forecast, Insider, Ratings, Fundamentals & Signals
-8.79% $3.32
America/New_York / 19 apr 2024 @ 16:00
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 109.08 mill |
| EPS: | -2.08 |
| P/E: | -1.600 |
| Earnings Date: | May 16, 2024 |
| SharesOutstanding: | 32.85 mill |
| Avg Daily Volume: | 0.0030 mill |
| RATING 2024-04-19 |
|---|
| B |
| Neutral |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Strong Buy | |
| Return On Equity: | Strong Sell | |
| Return On Asset: | Sell | |
| DE: | Neutral | |
| P/E: | Neutral | |
| Price To Book: | Sell |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | ||||||
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -1.600 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -0.27x |
| Company: PE -1.600 | industry: PE 5.88 |
| DISCOUNTED CASH FLOW VALUE |
|---|
|
$4.98 (50.11%) $1.664 |
| Date: 2024-04-20 |
| Expected Trading Range (DAY) |
|---|
|
$ 3.10 - 3.54 ( +/- 6.63%) |
| ATR Model: 14 days |
Forecast:
13:05 - $3.56
Live Trading Signals (every 1 min)
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 |
| Volume Signals | |
|---|---|
| Price | $3.32 (-8.79% ) |
| Volume | 0.0062 mill |
| Avg. Vol. | 0.0030 mill |
| % of Avg. Vol | 207.14 % |
| Signal 1: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For MOLN
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
MOLN
Molecular Partners AG operates as a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic proteins. Its products candidates include Abicipar, a DARPin therapeutic candidate, which is in Phase III clinical trials for the treatment of neovascular wet age-related macular degeneration, as well as for diabetic macular edema; and MP0420, a multi-specific DARPin therapeutic candidate for the SARS-CoV-2 virus. The company develops MP0310, which is in Phase Ia clinical trials for immuno-oncology; MP0317, a tumor-localized immune agonist that activates immune cells in the tumor, which is in Phase I clinical trials; and MP0274 that is in Phase I clinical trials for HER2-positive cancers. It also develops MP0423 for treating COVID-19; MP0533, a CD3 T cell candidate for acute myeloid leukemia; and MP0250 for vascular endothelial growth factor, hepatocyte growth factor, and human serum albumin to increase half-life. Molecular Partners AG has agreements and collaboration with Novartis AG to develop, manufacture, and commercialize DARPin-conjugated radioligand therapies; Amgen SA; Allergan, Inc.; and discovery alliance with AbbVie Inc. in ophthalmology, as well as other third-party collaborators. The company was incorporated in 2004 and is headquartered in Schlieren, Switzerland.
Latest Press Releases
2024-04-19 11:12:00 - Press Release
Life Science Cares Launches In Switzerland
First international chapter of life science cares established in switzerland – bringing hearts and minds together by empowering the life sciences industry to support local communities first international chapter of life science cares established in switzerland – bringing hearts and minds together by empowering the life sciences industry to support local communities
2024-04-17 11:12:00 - Press Release
Molecular Partners Announces All Board Proposals Approved At The Annual General Meeting
Zurich-schlieren, switzerland and concord, mass., april 17, 2024 (globe newswire) -- molecular partners ag (six: moln; nasdaq: moln), a clinical-stage biotech company developing a new class of custom-built protein drugs known as darpin therapeutics, today announced that all motions proposed by the board of directors at the annual general meeting were approved by the shareholders of the company by a wide majority.
2024-03-26 09:26:00 - Press Release
Molecular Partners Publishes Invitation To Annual General Meeting 2024
Zurich-schlieren, switzerland and concord, mass., march 26, 2024 (globe newswire) -- molecular partners ag (six: moln; nasdaq: moln), a clinical-stage biotech company developing a new class of custom-built protein drugs known as darpin therapeutics, today published the invitation to the annual general meeting 2024.
2024-03-14 16:00:00 - Press Release
Molecular Partners Reports Corporate Highlights From Q4 2023 And Key Financials For Full Year 2023
Research & development highlights presented encouraging initial data from first four dosing cohorts of ongoing phase 1/2a trial of mp0533 for patients with relapsed/refractory aml and aml/mds at the ash annual meeting, reporting an acceptable safety profile and initial anti-tumor activity introduced the switch-darpin concept and platform at pegs europe. in january 2024, introduced the first multispecific switch-darpin program, targeting ckit x cd16a x cd47, as a next-generation conditioning regimen for hematopoietic stem cell transplantation presented positive preclinical data supporting the radio-darpin therapy (rdt) platform and expansion of the rdt pipeline at multiple leading scientific conferences in january 2024, announced a strategic collaboration agreement with orano med to co-develop 212pb-based rdts for multiple oncology targets, including dll3 in january 2024, presented preclinical rdt data from the dll3 program showing enhanced tumor uptake and reduced kidney absorption presented updated positive data from the phase 1 trial of mp0317 for patients with advanced solid tumors at the sitc annual meeting, demonstrating cd40 activation in the tumor microenvironment while maintaining a favorable safety profile leadership & governance: dr...
2024-03-01 16:17:00 - Press Release
Molecular Partners Announces Dismissal Of Class Action Lawsuit
Zurich-schlieren, switzerland and concord, mass., march 01, 2024 (globe newswire) -- molecular partners ag (six: moln; nasdaq: moln), a clinical-stage biotech company developing a new class of custom-built protein drugs known as darpin therapeutics, today announced that a putative class action complaint against the company, its directors, and certain of its executive officers (the defendants) has been dismissed in the company's favor, and the case has been ordered closed.
Latest News
2024-03-15 11:20:08 - Seeking Alpha
Molecular Partners AG (MOLN) Q4 2023 Earnings Call Transcript
2024-03-01 16:00:00 - GlobeNewsWire
Molecular Partners To Hold Conference Call to Discuss Fourth Quarter and Full Year 2023 Results and Announces Upcoming Investor Presentations
ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., March 01, 2024 (GLOBE NEWSWIRE) -- Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics, today announced that it will issue its fourth quarter and full year financial results for 2023 on March 14, which will be followed by a conference call the next day to discuss the results.
2023-12-14 01:00:00 - GlobeNewsWire
Molecular Partners to Present at 42nd Annual J.P. Morgan Healthcare Conference and Swiss Investor Conferences
ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Dec. 14, 2023 (GLOBE NEWSWIRE) -- Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics, will present at the 42nd Annual J.P. Morgan Healthcare Conference taking place from January 8-11, 2024 in San Francisco, CA. In addition, members of Molecular Partners' leadership team will participate in upcoming investor events in Switzerland during January 2024. Conference Presentation Details
2023-11-14 01:00:00 - GlobeNewsWire
Molecular Partners to Present on DARPin Oncology Innovations at Protein & Antibody Engineering Summit Europe (PEGS)
ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Nov. 14, 2023 (GLOBE NEWSWIRE) -- Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics, will present on several of its programs at the 15th Annual Protein & Antibody Engineering European Summit (PEGS Europe), which runs November 14-16 in Lisbon, Portugal. The presentation will focus on the multiple ways Molecular Partners has designed DARPins to activate the immune system against cancer only under certain conditions. This conditional activation is intended to focus immune attack more specifically against tumor cells and minimize damage to healthy cells, a major challenge for current oncology drugs and development efforts.
2023-11-02 02:00:00 - GlobeNewsWire
Molecular Partners to Present Initial Data from Ongoing Phase 1/2a Trial of MP0533 for Patients with Relapsed/Refractory AML and AML/MDS at the 65th ASH Annual Meeting and Exposition
ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Ad hoc announcement pursuant to Art. 53 LR Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics, will present preliminary data from its ongoing Phase 1/2a trial of MP0533, a novel tetra-specific T cell engager at the 65th American Society of Hematology (ASH) Annual Meeting and Exposition being held from December 9–12 in San Diego, California. MP0533 is in development for the treatment of patients with relapsed/refractory acute myeloid leukemia (r/r AML) and myelodysplastic syndrome (AML/MDS).
2023-06-27 01:00:00 - GlobeNewsWire
Molecular Partners to Present on its Radio DARPin Therapy (RDT) Platform at SNMMI 2023
RDT platform offers unique approach for tailored delivery of radioactive payloads to solid tumors RDT platform is focused on improving both tumor-targeting efficiency and safety over historic protein-based radioligand approaches ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., June 27, 2023 (GLOBE NEWSWIRE) -- Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics, has announced it will present on its Radio DARPin Therapy (RDT) Platform at the 2023 Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting being held from June 24-27 in Chicago, Illinois.
2023-06-19 12:00:00 - GlobeNewsWire
Molecular Partners to Present at The TD Cowen Radiopharmaceutical Innovation Summit
ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., June 19, 2023 (GLOBE NEWSWIRE) -- Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics, today announced that the Company will present in a fireside chat at the TD Cowen Radiopharmaceutical Innovation Summit on Tuesday, June 20, 2023 at 12:00 p.m. ET. Presenting on behalf of Molecular Partners will be Patrick Amstutz, Chief Executive Officer, and Daniel Steiner, SVP Research.
2023-05-25 17:01:00 - GlobeNewsWire
Molecular Partners to Present Positive Data from Ongoing Phase 1 Trial of MP0317 (FAP X CD40) Monotherapy in Patients with Advanced Solid Tumors at the 2023 ASCO Annual Meeting
MP0317 demonstrates tumor-localized CD40 activation in tumor biopsies through target occupancy and immune cell activation
2023-05-16 16:00:00 - GlobeNewsWire
Molecular Partners to Participate in RBC Capital 2023 Global Healthcare Conference
ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., May 16, 2023 (GLOBE NEWSWIRE) -- Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics, today announced that Patrick Amstuts, Chief Executive Officer, will participate in the 2023 RBC Capital Markets Global Healthcare Conference, in-person, May 16-17, 2023.
2023-04-20 02:08:08 - Seeking Alpha
Molecular Partners: Sellers Have Disappeared, Enterprise Value Below Zero
